Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

Conditions:   Acute Lymphoblastic Leukemia;   Myeloblastic Leukemia;   Biphenotypic Acute Leukemia;   Malignant Lymphoma;   Myelodysplastic Syndromes;   Juvenile Myelomonocytic Leukemia Intervention:   Combination Product: GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor Sponsor:   Federal Research Institute of Pediatric Hematology, Oncology and Immunology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials